Avadel Pharmaceuticals (AVDL)
Bid | 9.44 |
Market Cap | 914.18M |
Revenue (ttm) | 194.45M |
Net Income (ttm) | -26.41M |
EPS (ttm) | -0.26 |
PE Ratio (ttm) | -36.35 |
Forward PE | 11.83 |
Analyst | Buy |
Ask | 9.47 |
Volume | 302,702 |
Avg. Volume (20D) | 1,106,746 |
Open | 9.20 |
Previous Close | 9.11 |
Day's Range | 9.07 - 9.46 |
52-Week Range | 6.38 - 17.30 |
Beta | 1.45 |
About AVDL
undefined
Analyst Forecast
According to 0 analyst ratings, the average rating for AVDL stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts
2 weeks ago · seekingalpha.com
Avadel Pharmaceuticals: Moving Nicely Through An 'Inflection Year'Avadel Pharmaceuticals is gaining momentum with strong Q1 results, a key legal win, and moving swiftly to profitability. LUMRYZ, Avadel's once-daily sodium oxybate, is growing rapidly and could enter ...

3 weeks ago · seekingalpha.com
Avadel Pharmaceuticals plc (AVDL) Q1 2025 Earnings Call TranscriptAvadel Pharmaceuticals plc (NASDAQ:AVDL ) Q1 2025 Earnings Conference Call May 7, 2025 9:00 AM ET Company Participants Austin Murtagh - IR Greg Divis - CEO Tom McHugh - CFO Conference Call Participant...

2 months ago · seekingalpha.com
Avadel Pharmaceuticals plc (AVDL) Q4 2024 Earnings Call TranscriptAvadel Pharmaceuticals plc (NASDAQ:AVDL ) Q4 2024 Earnings Conference Call March 3, 2025 8:30 AM ET Company Participants Austin Murtagh - Precision AQ Gregory Divis - Chief Executive Officer Thomas Mc...